Health & Fitness
Health and Fitness
Health and Fitness
Thu, July 1, 2010
Wed, June 30, 2010 
NORTH BRUNSWICK, N.J.--([ BUSINESS WIRE ])--[ Advaxis, Inc ]., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, and the [ Science and Technology Directorate ] of the [ Department of Homeland Security ] (DHS) have signed the previously announced cooperative research and development agreement (CRADA).
About Cooperative Research and Development Agreements
A Cooperative Research and Development Agreement (CRADA) is an agreement between the Federal government and private sector participants to work together on a mutually beneficial project. Each partner in the CRADA applies whatever resources are agreed to, such as personnel, equipment or facilities. While participant dollars may be used to fund portions of the government's effort, the government may not use Federal funds to support the private sector participant.
About the Science and Technology Directorate
The Science and Technology(S&T) Directorate is the primary research and development arm of the Department of Homeland Security. The S&T Directorate's mission is to improve homeland security by providing to customers state-of-the-art technology that helps them achieve their missions. S&T customers include the operating components of the Department, and state, local, tribal and territorial emergency responders and officials. The Directorate has three portfolios that address basic research through advanced technology development and transition - spanning six primary divisions that address critical homeland security needs. For additional information: [ http://www.dhs.gov/xabout/structure/editorial_0530.shtm ]
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeriamonocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the [ City of Hope ], the [ Roswell Park Cancer Institute ], the [ National Cancer Institute ], the [ University of Pittsburgh ] and [ Cancer Research a" UK ]. Advaxisa™ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxisa™ scientific advisory board.
Please visit the Companya™s portals: [ advaxis.com ] | [ facebook ] | [ twitter ] | [ LinkedIn ]
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties.The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.Forward-looking statements deal with the Companya™s current plans, intentions, beliefs and expectations and statements of future economic performance.Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated.Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.The Company cannot guarantee its future results, levels of activity, performance or achievements.
